Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep 10:10:569-75.
doi: 10.2147/VHRM.S63199. eCollection 2014.

Economic and outcomes consequences of TachoSil®: a systematic review

Affiliations

Economic and outcomes consequences of TachoSil®: a systematic review

Giorgio L Colombo et al. Vasc Health Risk Manag. .

Abstract

Background: TachoSil(®) is a medicated sponge coated with human fibrinogen and human thrombin. It is indicated as a support treatment in adult surgery to improve hemostasis, promote tissue sealing, and support sutures when standard surgical techniques are insufficient. This review systematically analyses the international scientific literature relating to the use of TachoSil in hemostasis and as a surgical sealant, from the point of view of its economic impact.

Methods: We carried out a systematic review of the PubMed literature up to November 2013. Based on the selection criteria, papers were grouped according to the following outcomes: reduction of time to hemostasis; decrease in length of hospital stay; and decrease in postoperative complications.

Results: Twenty-four scientific papers were screened, 13 (54%) of which were randomized controlled trials and included a total of 2,116 patients, 1,055 of whom were treated with TachoSil. In the clinical studies carried out in patients undergoing hepatic, cardiac, or renal surgery, the time to hemostasis obtained with TachoSil was lower (1-4 minutes) than the time measured with other techniques and hemostatic drugs, with statistically significant differences. Moreover, in 13 of 15 studies, TachoSil showed a statistically significant reduction in postoperative complications in comparison with the standard surgical procedure. The range of the observed decrease in the length of hospital stay for TachoSil patients was 2.01-3.58 days versus standard techniques, with a statistically significant difference in favor of TachoSil in eight of 15 studies.

Conclusion: This analysis shows that TachoSil has a role as a supportive treatment in surgery to improve hemostasis and promote tissue sealing when standard techniques are insufficient, with a consequent decrease in postoperative complications and hospital costs.

Keywords: TachoSil®; cost analysis; economic evaluation; outcomes research; systematic review.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of the selection process to identify studies to be included.

References

    1. Harmon DE. Cost/benefit analysis of pharmacologic hemostasis. Ann Thorac Surg. 1996;61(Suppl 2):S21–S25. - PubMed
    1. Hartmann M, Sucker C, Boehm O, Koch A, Loer S, Zacharowski K. Effects of cardiac surgery on hemostasis. Transfus Med Rev. 2006;20:230–241. - PubMed
    1. Regione Emilia Romagna, Commissione Regionale Dispositivi Medici (Delibera Giunta Regionale n. 1523/2008) Emostatici locali e sigillanti chirurgici Dalle evidenze della letteratura alla pratica quotidiana. Novembre. 2012. [Accessed November 28, 2013]. Available from: http://www.saluter.it/documentazione/rapporti/emostatici_novembre2012.pdf. Italian.
    1. Vonlanthen R, Slankamenac K, Breitenstein S, et al. The impact of complications on costs of major surgical procedures: a cost analysis of 1200 patients. Ann Surg. 2011;254:907–913. - PubMed
    1. Sundaram CP, Keenan AC. Evolution of hemostatic agents in surgical practice. Indian J Urol. 2010;26:374–378. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources